Nikkei hits 10-mth closing high, exporters weigh
2009-08-11 02:55:00.0
(Reuters) - Japan's Nikkei average hit its highest close in 10 months on Tuesday, with construction stocks such as Obayashi Corp (
) surged over 9 percent after a brokerage initiated its coverage with a "buy" rating, while drugmaker Daiichi Sankyo (
"The Nikkei's current level of around 10,500-11,000 is based on investor expectations for a 'V-shaped' recovery in earnings in the next business year," said Mitsushige Akino, chief fund manager at Ichiyoshi Investment Management.
During the Tokyo market's midday break, the BOJ announced it was keeping interest rates on hold and maintained its cautious view on the economy. [ID:nT328059]
Meanwhile, China reported below-forecast growth in factory output and investment, underlining why senior officials keep reminding markets that recovery in the world's third-largest economy is not yet on solid ground. [ID:nPEK216341]
In light trade, the benchmark Nikkei
rose 0.6 percent or 61.20 points to 10,585.46, its highest finish since Oct. 3.
added 0.4 percent to 973.51. The Nikkei's next target is likely to be 10,800 -- a 50 percent Fibonacci retracement from its June 2008 high and last October's 26-year low just under 7,000 -- followed by 11,000, roughly the level from which it fell rapidly after Lehman Brothers failed last September.
In the short-term, market participants are awaiting the results of the Federal Reserve's two-day meeting which ends on Wednesday.
), Yamaha Motor (
), Panasonic (
), Sony (
) said they had not seen damage to their factories in the area of the quake on Tuesday morning, which was centred southwest of Tokyo. [ID:nT322240]
But construction shares gained on expectations for reconstruction efforts after recent floods and the earthquake, market players said. They added the sector was also playing catch-up as it lagged behind during the market recovery-run led by exporters.
Obayashi Corp jumped 5.2 percent to 445 yen, Shimizu Corp (
Nippon Sheet Glass surged 9.2 percent to 355 yen after Bank of America Merrill Lynch initiated coverage with a "buy" rating, citing expectations of a significant earnings contribution from price hikes on European construction-use glass.
Daiichi Sankyo climbed 5 percent to 1,908 yen after it and Australian biotech firm Biota BTA.AX said on Monday that a new flu drug has succeeded in late-stage trials in Asia. Daiichi Sankyo holds the Japan rights to manufacture and market the drug.
But Astellas Pharma lost 4.9 percent to 3,690 yen, while exporter shares took a breather. Honda slid 2.8 percent to 3,120 yen and electronics components maker TDK Corp (
) shed 2.5 percent to 5,370 yen.
Some 1.9 billion shares changed hands on the Tokyo exchange's first section, below last week's daily average of 2.1 billion.
